Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

BACKGROUND: Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph-positive ALL) is frequently caused by mutations in the BCR-ABL kinase domain. Ponatinib (AP24534) is a potent oral tyrosine kinas...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Cortes, Jorge E., Kantarjian, Hagop, Shah, Neil P., Bixby, Dale, Mauro, Michael J., Flinn, Ian, O'Hare, Thomas, Hu, Simin, Narasimhan, Narayana I., Rivera, Victor M., Clackson, Tim, Turner, Christopher D., Haluska, Frank G., Druker, Brian J., Deininger, Michael W.N., Talpaz, Moshe
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3777383/
https://ncbi.nlm.nih.gov/pubmed/23190221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1205127
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky